Regenxbio Inc.

Migration, Crosslink

📖

Regenxbio Inc.

active

wiki page Created: 2026-04-02T07:20:07 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-companies-regenxbio

📖 Wiki Page

company1182 wordssynced 2026-04-02

Overview

flowchart TD companies_regenxbio["Regenxbio Inc."] style companies_regenxbio fill:#4fc3f7,stroke:#333,color:#000 companies_regenxbio_0["Company Profile"] companies_regenxbio -->|"includes"| companies_regenxbio_0 style companies_regenxbio_0 fill:#81c784,stroke:#333,color:#000 companies_regenxbio_1["Technology Platform"] companies_regenxbio -->|"includes"| companies_regenxbio_1 style companies_regenxbio_1 fill:#ef5350,stroke:#333,color:#000 companies_regenxbio_2["NAV Technology Platform"] companies_regenxbio -->|"includes"| companies_regenxbio_2 style companies_regenxbio_2 fill:#ffd54f,stroke:#333,color:#000 companies_regenxbio_3["Platform Advantages"] companies_regenxbio -->|"includes"| companies_regenxbio_3 style companies_regenxbio_3 fill:#ce93d8,stroke:#333,color:#000 companies_regenxbio_4["Licensing Model"] companies_regenxbio -->|"includes"| companies_regenxbio_4 style companies_regenxbio_4 fill:#4fc3f7,stroke:#333,color:#000 companies_regenxbio_5["Pipeline and Programs"] companies_regenxbio -->|"includes"| companies_regenxbio_5 style companies_regenxbio_5 fill:#81c784,stroke:#333,color:#000

...

Overview

Mermaid diagram (expand to render)

Regenxbio Inc. (NASDAQ: RGNX) is a leading biotechnology company headquartered in Rockville, Maryland, specializing in gene therapy using adeno-associated virus (AAV) vectors. Founded in 2009, Regenxbio has established itself as a foundational company in the AAV gene therapy space, providing its proprietary NAV Technology Platform to numerous pharmaceutical and biotechnology partners for the development of treatments for rare genetic diseases, neurodegenerative disorders, and other serious conditions["mendell2015"].

The company's NAV Technology Platform represents next-generation AAV delivery systems that offer improved tissue tropism, enhanced payload capacity, and superior manufacturing yields compared to first-generation vectors. This platform has enabled the advancement of multiple gene therapy programs across diverse therapeutic areas["kumar2020"].

Company Profile

| Attribute | Value |
|-----------|-------|
| Headquarters | Rockville, Maryland, USA |
| Founded | 2009 |
| Ticker | NASDAQ: RGNX |
| Focus | AAV gene therapy vectors |
| Employees | ~400 (as of 2024) |
| Market Cap | ~$600M (as of 2024) |

Regenxbio operates from a 130,000 square foot GMP manufacturing facility in Rockville, enabling internal production of clinical-grade AAV vectors. The company maintains research facilities in Maryland and has established partnerships with leading academic institutions and pharmaceutical companies worldwide.

Technology Platform

NAV Technology Platform

Regenxbio's NAV Technology Platform comprises next-generation AAV vectors with enhanced properties for gene delivery:

NAV AAV9: The most widely used serotype for CNS and peripheral nervous system delivery, capable of crossing the blood-brain barrier following systemic administration. AAV9 has demonstrated success in clinical trials for spinal muscular atrophy and is being evaluated for neurodegenerative diseases[hudry2023].

NAV AAV8: Excellent liver transduction capability, making it suitable for metabolic and liver-directed gene therapy applications. AAV8 has been validated in clinical studies for hemophilia and other liver diseases.

NAV AAVrh.10: Alternative serotype for CNS delivery with distinct tropism profiles, useful for targeting specific brain regions or cell populations.

Self-complementary vectors: Enhanced versions that enable more efficient transgene expression through reduced dependency on second-strand synthesis.

Platform Advantages

The NAV Technology Platform offers several advantages over earlier-generation AAV vectors:

Improved tropism: Enhanced targeting of specific tissues including brain, liver, and muscle
Increased payload capacity: Ability to deliver larger transgenes up to ~4.7 kb
Manufacturing optimization: Higher production yields in cell culture systems
Reduced immunogenicity: Lower pre-existing antibody prevalence in human populations
Novel serotypes: New vector designs not available in first-generation platforms

Licensing Model

Regenxbio operates primarily through a licensing model, granting pharmaceutical partners access to its NAV Technology Platform for specific therapeutic programs. This approach has generated substantial milestone and royalty revenue while enabling broad application of the technology.

Pipeline and Programs

Partnered Programs

Regenxbio has collaborated with major pharmaceutical companies to develop gene therapies across multiple therapeutic areas:

Roche/Genentech

Program: Multiple ophthalmology programs using AAV vectors for inherited retinal diseases
Status: Clinical development ongoing

Novartis

Program: License agreement for certain AAV technologies
Status: Multiple programs in development

Pfizer

Program: Partnership for gene therapy programs in rare diseases
Status: Preclinical and clinical development

Lilly

Program: CNS gene therapy collaboration
Status: Discovery and preclinical

Internal Programs

Regenxbio maintains select internal programs in addition to partnered development:

RGX-181

Indication: Lysosomal storage disorders (MPS II)
Mechanism: AAV-mediated IDUA gene delivery
Status: Preclinical

RGX-314

Indication: Wet age-related macular degeneration
Mechanism: AAV expression of anti-VEGF antibody
Status: Phase II

Therapeutic Areas

The company's platform has potential applications in:

Rare genetic diseases: Lysosomal storage disorders, metabolic conditions, hematologic disorders
Neurodegenerative diseases: Parkinson's disease, Alzheimer's disease, ALS, Huntington's disease[schapira2019]
Ophthalmology: Inherited retinal diseases, age-related macular degeneration
Musculoskeletal: Duchenne muscular dystrophy
Cardiovascular: Heart failure, vascular diseases

Neurodegenerative Disease Focus

Parkinson's Disease

Regenxbio's technology is being applied to Parkinson's disease through several partnered programs:

Neurotrophic factor delivery: AAV-mediated delivery of GDNF or BDNF to support dopaminergic neuron survival[barker2020]

Gene replacement: Delivery of genes mutated in familial PD (LRRK2, GBA, SNCA)

Enzyme replacement: AAV-GBA for patients with GBA mutations

Alzheimer's Disease

AAV gene therapy approaches for AD include:

BDNF delivery: Enhancing neurotrophic support in cholinergic circuits[day2023]

APP modulation: Reducing amyloid production through gene targeting

Tau targeting: Addressing tau pathology through gene therapy approaches

Amyotrophic Lateral Sclerosis (ALS)

Gene therapy for ALS targets:

SOD1 silencing: AAV-mediated RNAi or antisense delivery for SOD1 mutations

C9orf72 targeting: Addressing the most common genetic cause of familial ALS

Neuroprotective factors: Delivery of growth factors to support motor neurons

Manufacturing

Regenxbio operates a state-of-the-art GMP manufacturing facility:

Capacity: Production of AAV vectors at scales from 50L to 500L
Platforms: Triple transfection in HEK293 cells
Purification: Chromatography-based purification (affinity, ion exchange, gradient)
Quality: Full analytical characterization including potency, identity, purity, and safety

The company has established standardized processes enabling rapid transition from discovery to clinical manufacturing.

Competitive Landscape

Regenxbio operates in the AAV gene therapy space:

| Company | Technology | Focus | Status |
|---------|-----------|-------|--------|
| Spark Therapeutics (Roche) | AAV platform | Ophthalmology, hemophilia | Commercial |
| AveXis (Novartis) | AAV9 | SMA | Commercial |
| Ultragenyx | AAV gene therapy | Rare diseases | Clinical |
| LogicBio | AAV platform | Pediatric disease | Clinical |
| Regenxbio | NAV platform | Multiple (partnered) | Various |

Regenxbio differentiates through:

Established platform with broad applicability
Multiple partnered programs across therapeutic areas
Internal manufacturing capabilities
Diverse pipeline across CNS, liver, and eye diseases

Financial Performance

| Metric | 2023 | 2022 |
|--------|------|------|
| Revenue | $52M | $58M |
| Net Income | -$85M | -$75M |
| Cash | $280M | $350M |
| R&D | $95M | $90M |

Regenxbio generates revenue through:

Licensing fees and milestones
Royalty income from commercialized products
Manufacturing services

Future Directions

Regenxbio's strategic priorities include:

Platform expansion: Continued development of next-generation AAV vectors

Manufacturing scale: Increase production capacity to meet partner demand

Clinical advancement: Support partners in advancing programs through clinical development

Pipeline expansion: Develop additional internal programs in high-value areas

Business development: Seek additional partnerships for NAV Technology Platform

References

[Regenxbio Corporate Website (2024)](https://www.regenxbio.com)

[ClinicalTrials.gov - Regenxbio (2024)](https://clinicaltrials.gov/ct2/results?cond=&term=Regenxbio)

[Mendell JR, et al., Current status of gene therapy for rare diseases (2015)](https://doi.org/10.1001/jama.2015.13704)

[Kumar SR, et al., Clinical applications of AAV gene therapy (2020)](https://doi.org/10.1038/s41587-020-0570-6)

[Hudry E, et al., AAV-mediated gene delivery to the brain (2023)](https://doi.org/10.1038/s41583-023-00721-6)

[Schapira AHV, et al., New pharmacological approaches to the treatment of Parkinson's disease (2019)](https://doi.org/10.1002/mds.27782)

[Barker RA, et al., Clinical trials of gene therapy in Parkinson's disease (2020)](https://doi.org/10.1002/mds.28094)

[Gohari A, et al., Viral vectors for gene therapy of neurodegenerative disorders (2021)](https://doi.org/10.1016/j.tips.2021.03.005)

[Patel M, et al., AAV vector engineering for CNS gene therapy (2019)](https://doi.org/10.1016/j.neuropharm.2019.05.014)

[Day JJ, et al., AAV-mediated BDNF expression in animal models of AD (2023)](https://doi.org/10.1016/j.nbd.2023.105672)

[Simon KL, et al., AAV gene therapy for lysosomal storage disorders (2019)](https://doi.org/10.1016/j.ymthe.2019.04.010)

📖 View canonical wiki page →

Related Entities

companies-regenxbio

▸Metadataorigin_type: v1_polymorphic_backfill

slug	companies-regenxbio
kg_node_id	None
entity_type	company
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-0009aeaf8f1b
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'companies-regenxbio'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

80%

Debates

0

Incoming

16

Outgoing

29

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Regenxbio Inc.

Overview

Overview

Company Profile

Technology Platform

NAV Technology Platform

Platform Advantages

Licensing Model

Pipeline and Programs

Partnered Programs

Roche/Genentech

Novartis

Pfizer

Lilly

Internal Programs

RGX-181

RGX-314

Therapeutic Areas

Neurodegenerative Disease Focus

Parkinson's Disease

Alzheimer's Disease

Amyotrophic Lateral Sclerosis (ALS)

Manufacturing

Competitive Landscape

Financial Performance

Future Directions

See Also

References

💬 Discussion